Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
960.00M | 1.01B | 1.05B | 1.12B | 1.79B | 1.56B | Gross Profit |
303.40M | 305.20M | 343.90M | 427.20M | 1.04B | 1.03B | EBIT |
-54.20M | -108.70M | -726.40M | -166.00M | 352.60M | 433.80M | EBITDA |
106.30M | 36.90M | -505.30M | -32.90M | 458.20M | 549.00M | Net Income Common Stockholders |
-131.60M | -190.60M | -760.50M | -223.80M | 219.50M | 305.80M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
99.50M | 99.50M | 111.70M | 642.60M | 576.10M | 621.30M | Total Assets |
1.39B | 1.39B | 1.82B | 3.17B | 2.96B | 2.88B | Total Debt |
663.70M | 663.70M | 860.20M | 1.41B | 841.00M | 874.80M | Net Debt |
564.20M | 564.20M | 748.50M | 763.20M | 264.90M | 253.50M | Total Liabilities |
906.90M | 906.90M | 1.17B | 1.78B | 1.34B | 1.44B | Stockholders Equity |
482.80M | 482.80M | 649.30M | 1.38B | 1.62B | 1.45B |
Cash Flow | Free Cash Flow | ||||
94.40M | 35.80M | -257.90M | -149.90M | 96.10M | 395.00M | Operating Cash Flow |
110.10M | 58.70M | -206.30M | -34.10M | 321.10M | 536.00M | Investing Cash Flow |
195.50M | 125.20M | 212.30M | -381.30M | -225.00M | -151.00M | Financing Cash Flow |
-231.10M | -190.00M | -535.70M | 481.20M | -141.00M | 69.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $434.36M | 9.13 | 25.47% | 10.13% | -23.37% | -39.03% | |
67 Neutral | $1.34B | ― | -5.19% | ― | 30.26% | -173.36% | |
61 Neutral | $341.95M | ― | -21.63% | ― | -18.56% | 76.88% | |
53 Neutral | $5.23B | 3.23 | -44.27% | 2.82% | 16.82% | 0.11% | |
48 Neutral | $1.18B | 64.45 | -10.45% | ― | 24.76% | -783.38% | |
46 Neutral | $254.36M | ― | -83.58% | ― | 6.88% | -17.54% | |
45 Neutral | $279.11M | ― | 77.48% | ― | 5.29% | -37.31% |
On May 9, 2025, the United States District Court for the District of Maryland granted preliminary approval for a proposed settlement of shareholder derivative actions against Emergent BioSolutions Inc. The settlement, which includes no admission of fault by the defendants, addresses allegations of fiduciary breaches related to the company’s Bayview facility and its role in manufacturing COVID-19 vaccines. The court has scheduled a hearing for August 6, 2025, to determine final approval. The allegations claimed that Emergent’s management failed to ensure regulatory compliance, leading to significant financial losses and legal challenges.
The most recent analyst rating on (EBS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.
Emergent BioSolutions reported a significant financial turnaround in the first quarter of 2025, with a net income increase of 656% despite a 26% drop in total revenues compared to the previous year. The company attributes this improvement to its strategic plan aimed at stabilizing operations and enhancing profitability, as evidenced by increased gross and EBITDA margins. Recent business developments include securing contracts with the U.S. Department of Defense and other international orders, as well as strategic partnerships and asset sales, all of which are expected to support future growth and stability.
On April 30, 2025, Emergent BioSolutions Inc. held its annual meeting of stockholders, where approximately 67% of the company’s shares were represented. During the meeting, stockholders elected three Class I directors, ratified the appointment of Ernst & Young LLP as the company’s independent auditor for 2025, and approved the 2024 compensation for the company’s named executive officers.
On March 10, 2025, Emergent BioSolutions announced the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for $36.5 million. The agreement allows Emergent to retain rights to manufacturing services at the facility for future growth and pandemic response. This transaction is part of Emergent’s multi-year transformation plan to streamline operations and enhance its manufacturing network, which includes facilities in Lansing, Michigan, and Winnipeg, Canada. The sale is expected to close in the first quarter of 2025, following customary closing conditions.